No increased risk of coronary heart disease for patients receiving androgen deprivation therapy for prostate cancer in Chinese/Taiwanese men

Andrology

Volumn 4, Issue 1, 2016, Pages 128-132

  Wang, L H ^a,b   Liu, C K ^c,d   Chen, C H ^e   Kao, L T ^f   Lin, H C ^b   Huang, C Y ^a,g  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

^d FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Androgen deprivation therapy; Coronary heart diseases; Epidemiology

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CONTROLLED STUDY; CORONARY RISK; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; TAIWANESE; COHORT ANALYSIS; CORONARY DISEASE; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; RISK FACTOR; TAIWAN;

AGED; ANDROGEN ANTAGONISTS; COHORT STUDIES; CORONARY DISEASE; HUMANS; MALE; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; TAIWAN;

EID: 84955184312     PISSN: 20472919     EISSN: 20472927     Source Type: Journal    
DOI: 10.1111/andr.12141     Document Type: Article

References (27)

1. Alibhai SM, Duong-Hua M, Sutradhar R, Fleshner NE, Warde P, Cheung AM & Paszat LF. (2009) Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 27, 3452-3458.
2. American Cancer Society (2015) Cancer Facts & Figures 2015. Atlanta American Cancer Society.
3. Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Billiet I, Torecilla JL, Pfeffer R, Cutajar CL, Van der Kwast T & Collette L. (2010) External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 11, 1066-1073.
4. Brawley OW. (2012) Prostate cancer epidemiology in the United States. World J Urol 30, 195-200.
5. Chen HM, Lin CC, Kang CS, Lee CT, Lin HC & Chung SD. (2014) Bladder pain syndrome/interstitial cystitis increase the risk of coronary heart disease. Neurourol Urodyn 33, 511-515.
6. Collier A, Ghosh S, McGlynn B & Hollins G. (2012) Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review. Am J Clin Oncol 35, 504-509.
7. Dennis LK, Lynch CF & Torner JC. (2002) Epidemiologic association between prostatitis and prostate cancer. Urology 60, 78-83.
8. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM & Smith MR. (2008) Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol 54, 816-823.
9. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM & Smith MR. (2009) Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 27, 92-99.
10. Farkouh ME & Greenberg BP. (2009) An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol 103, 1227-1237.
11. Gandaglia G, Sun M, Popa I, Schiffmann J, Abdollah F, Trinh QD, Saad F, Graefen M, Briganti A, Montorsi F & Karakiewicz PI. (2014) The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study. BJU Int 114, E82-E89.
12. Hermann M. (2009) Cardiovascular risk associated with nonsteroidal anti-inflammatory drugs. Curr Rheumatol Rep 11, 31-35.
13. Huang G, Yeung CY, Lee KK, Liu J, Ho KL, Yiu MK, Lam KS, Tse HF, Yau T & Siu CW. (2014) Androgen deprivation therapy and cardiovascular risk in chinese patients with nonmetastatic carcinoma of prostate. J Oncol 2014, 529468.
14. Jespersen CG, Norgaard M & Borre M. (2014) Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol 65, 704-709.
15. Kang JH & Lin HC. (2010) Increased risk for coronary heart disease after avascular necrosis of femoral head: a 3-year follow-up study. Am Heart J 159, 803-808.
16. Morgans AK, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Stanford JL, Stroup AM, Resnick MJ, Barocas DA & Penson DF. (2015) Influence of age on incident diabetes and cardiovascular disease in prostate cancer survivors receiving androgen deprivation therapy. J Urol 193, 1226-1231.
17. Namiki M, Ueno S, Kitagawa Y, Fukagai T & Akaza H. (2012) Effectiveness and adverse effects of hormonal therapy for prostate cancer: Japanese experience and perspective. Asian J Androl 14, 451-457.
18. Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, Beckman JA & Choueiri TK. (2011) Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 306, 2359-2366.
19. O'Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P & Van Hemelrijck M. (2015) Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 33, 1243-1251.
20. Omabe M & Ezeani M. (2011) Infection, inflammation and prostate carcinogenesis. Infect Genet Evol 11, 1195-1198.
21. Punnen S, Cooperberg MR, Sadetsky N & Carroll PR. (2011) Androgen deprivation therapy and cardiovascular risk. J Clin Oncol 29, 3510-3516.
22. Roach M 3rd, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, Lawton C, Valicenti R, Grignon D & Pilepich MV. (2008) Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 26, 585-591.
23. Sfanos KS & De Marzo AM. (2012) Prostate cancer and inflammation: the evidence. Histopathology 60, 199-215.
24. Sharifi N, Gulley JL & Dahut WL. (2005) Androgen deprivation therapy for prostate cancer. JAMA 294, 238-244.
25. Torimoto K, Samma S, Kagebayashi Y, Chihara Y, Tanaka N, Hirayama A, Fujimoto K & Hirao Y. (2011) The effects of androgen deprivation therapy on lipid metabolism and body composition in Japanese patients with prostate cancer. Jpn J Clin Oncol 41, 577-581.
26. Tunio M, Rafi M, Qayyum A & Hashmi A. (2010) Androgen deprivation therapy increases the risk of diabetes and non-cancer mortality in prostate cancer patients: a metaanalysis. J Diabetol 2, 1-7.
27. Zhao J, Zhu S, Sun L, Meng F, Zhao L, Zhao Y, Tian H, Li P & Niu Y. (2014) Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. PLoS ONE 9, e107516.